ldiotypic determinants on neoplastic B cells could provide tumor antigens for vaccination of patients with B-cell tumors. Because this approach requires an individual vaccine for each patient, simple methods for obtaining idiotypic antigen are desirable. Using polymerase chain reaction (PCR) with family-based V-gene and J-region primers, the variable region genes of heavy and light chains (VH and V,) of Ig have been obtained from biopsy material from 13 patients with B-cell tumors. In each case, analysis of random clones derived from the PCR product showed repeated, clonally-related sequences, whereas normal lymphoid tissue generated no repeated sequences. In 313 cases, the repeated sequences were found to be the same as those in a tumor-derived hybridoma. Mutational patterns in the V-genes differed among HE IDEA OF vaccinating patients against their tumor has always been attractive, but has been difficult to pursue because of a lack of molecularly defined tumor-associated antigens. For B-cell tumors, the variable region sequences of the surface Ig of the tumor cell do provide a defined tumor-associated antigenic complex that could act as a target for immune attack by the host. However, for clonal tumor antigens of this nature, there is the technical difficulty of preparing individual vaccines for each patient within an appropriate time-scale.'
the tumors, with follicular lymphoma tending to be more highly mutated. The individual VH and VL sequences have been assembled with a flexible linker sequence to encode single-chain Fv (scFv). The scFv sequences can be cloned into bacterial expression vectors to produce protein, or into vectors suitable for direct vaccination using naked DNA. In a model system, expressed scFv protein retained all idiotypic determinants defined by a panel of five anti-idiotypic monoclonal antibodies (MoAbs). Similarly, expressed scFv proteins from two patients were shown to react with antiidiotypic antibodies. This approach allows production of potential vaccines from surgical biopsies within 2 to 3 weeks.
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of patients' material, and the preparation of individual patient vaccines that consist of single-chain Fv (scFv) molecules either as protein or as naked DNA.
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Preparation of DNA and cDNA. For isolation of DNA, 1 O6 cells were washed with I X PCR buffer (Boehringer, Mannheim, Germany). resuspended in 1 mL of K buffer (1 x PCR buffer, 0.5% Tween-20) and digested with Proteinase K (100 pg/mL) at 56°C for 1 hour. Proteinase K was inactivated by heating to 95°C for 30 minutes, 5 ,ILL used for the PCR reaction and the remainder kept at -20°C. For isolation of RNA, mononuclear cell populations were lysed with RNAzol B (Cinna Biotecxlabs Inc, Houston, TX) and precipitated with isopropanol. First-strand cDNA was synthesized from 5 pg of total RNA, using a first-strand cDNA synthesis kit and an oligo(dT) primer.
Primers for PCR. For amplification from DNA, 5' primers based in framework region I (FWR1) of the VH and VK sequences were used ( Table 1) . These primers are similar to those described previously? but have been shortened by one base at the 3' end to give a cleaner product. In addition, the number of primers was reduced by combining similar primers as one consensus primer ( Table   1 ).
Limited sequence information was available on which to base the VX primers, but primers were made to VXI, VX2, VX3 and VX4 families from the available sequence data.' More recently, a detailed analysis of the VX germline genes has been made," and additional primers, designed from the new sequences, can been used. The Jregion primers were made complementary to the genomic sequence of the germline J-regions for heavy chain, K chain, and X chain' ( Table l) . The JX genes combine their respective CA genes, and because CA4, 5, and probably 6 are pseudogenes, they should not produce protein; therefore, primers to these were not made. The other primers were used in the combinations indicated in Table 1 .
In some cases, where tissue was sufficiently fresh, the PCR for V, was performed on cDNA; this proredure gives a cleaner product and reduces the possibility of a contnbut~on from an aberrantly rearranged allelic chromosome. It also provides a second approach in cases where there are mutations in the FWRl. For this amplification, either the VH primers listed in Table 1 , or mixtures of oligonucleotide primers specific for each of the VH leader sequences of the VHI through VH6 families" were used, together with the J-region primers above.
PCR amplz'cafion of V-genes. In all cases, PCR was performed in a final volume of 50 pL with 20 pmol of each primer, 50 pmol of deoxynucleotide triphosphate and 2.5 U of Taq DNA polymerase with reaction buffer (Boehringer). Amplification consisted of an initial denaturation step of 5 minutes at 94T, followed by 35 cycles of 94°C for I minute; 56°C for 1 minute or 65°C for 1 minute for VH and VL, respectively; and 72°C for 1 minute, with a final extension step of 5 minutes at 72°C. Amplified variable regions were analyzed on a 1.5% low-melting point (LMP) agarosemris acetate-EDTA (TAE) gel and visualized with ethidium bromide. The band of the expected size was excised and purified by absorption and elution onto glass particles (GENECLEAN I1 kit; BiolOl, Vista, CA) according to manufacturer's instructions. At least two independent PCR amplifications were performed from each sample, and the PCR of lymph node material was performed before the corresponding PCR from the heterohybridomas.
Cloning and sequencing of PCR products. For cloning, purified products were ligated into pCRTMII vector and introduced into INVaF'-competent Escherichia coli cells (Invitrogen, San Diego, CA). Clones found to contain an insert of appropriate size by restriction analysis of plasmid DNA were sequenced by the dideoxy chain termination method with T7 DNA polymerase (Pharmacia) and the -20 universal primer. Sequence alignment analysis was performed by searching GENBANK and current databases' using MacVector 4.0 sequence analysis software (Eastman Kodak CO, New Haven, CT).
i . .
Assembly of V-genes as scFv. The assembly method, illustrated in Fig I , is based on that described previously." The process of assembly requires a second set of primers that are listed in Table 1 The VHSjBACK primers encode an S ' cloning site and also hybridize to the original set of VHBACK primers. The scJHFOR and SCVKI VXBACK primers hybridize to their respective initial primers, but also encode the sc linker to allow production of an scFv." The NofJdJAFOR primers similarly hybridize to their respective initial primers, but also include the Not I restriction site (Table l) .
Assembly is performed in two stages: first, V, and V, genes were amplified from the sequencing template using the new set of oligonucleotides. The PCR mixture was made up as above, but the primers used were only the relevant V-gene family and J-region primers identified by previous sequencing. The template was 1 0 0 ng of ss-DNA sequencing template, and PCR conditions were 94°C for 1 minute, 50°C for 1 minute, 74°C for 1 minute, with 10 cycles of amplification. After this step, the product was gel purified as above and resuspended in 25 pL of water. Samples (5 pL) from each of the products obtained from heavy and light chain were then assembled. For this process, the PCR reaction was performed in two steps. Initially no primers were added and the following cycles were used: 94°C for 1 minute, 50°C for 1 minute, 74°C for 1 minute, for 7 cycles to join the heavy and light chains. During the secondary PCR described above, the heavy and light chains are tagged with primers encoding the single-chain linker. This tag contains IS nucleotides on each of the heavy and light chains complementary to each other and thus allows them to anneal to each other. During the extension reaction, full-length joined scFv molecules are formed. At the end of these 7 cycles, the temperature is held at 94°C for 3 minutes and the relevant outer primers (SjiV,BACWNofJFOR) added for the "pull-through" amplification. This amplification consists of 10 cycles of 94°C for I minute and 74°C for 2 minutes, and serves to amplify the small amount of linked product formed.
Cloning for expression; expression and purijication of scFv. After assembly, the scFv was digested with S ' VNof 1 as described," and cloned into a scFv expression vector, based on pUCl 19.16 A vector containing the c-myc tag was used to check expression of scFv by Western blotting. However, to allow purification using metal affinity chromatography (see below), a modified expression vector, pRH2, which has the c-myc tag replaced by a hexahistidine tag, was used. The modification was performed by inverted PCR site-directed mutagenesis," and the vector sequences are shown in Fig 2. To check for expression of full length scFv, individual colonies were picked and grown for 4 hours with constant shaking in 1 mL 2 X Treptone Yeast (TY)/O.I% glucose/100 pg/mL ampicillin at 30°C. At that stage, isopropyl-p-D-thiogalactopyranoside (IPTG) was added to a final concentration of 1 mmol/L and shaking was continued for 18 hours. The supernatant was then harvested by centrifugation at 13,000 rpm in a microcentrifuge for 5 minutes, before analysis by Western blotting using the 9EI0 anti-myc MoAb.l* The bacterial pellet was frozen at -20°C for preparation of plasmid DNA.
For purification of scFv, the assembled product was subcloned as an S ' I/Nof I fragment from the plasmid preparation from a colony shown to express scFv. One-liter cultures of bacteria were grown with constant shaking in 2-L flasks containing 2 X TY/O. 1 % glucose/ 100 pg/mL ampicillin at 30°C to an Am of 0.9. At this stage, IPTG was added to a final concentration of 1 mmol/L and the incubation continued for a further 4 hours. The bacteria were then pelleted by centrifugation and the periplasmic fraction prepared as described."
The scFv antibody fragment was purified from the periplasmic fraction by using the hexahistidine tag. The method is based on that described,'" but it was found that the use of six histidines and nickel rather than five histidines and zinc was preferable (data not shown). The periplasmic preparation from a l-L culture was loaded onto a I-mL column of chelating Sepharose Fast Flow (Pharmacia) previously coupled with nickel ions according to the manufacturer's instructions. The column was then washed with 10 mL of PBSll m o m NaCl (pH 7.2) followed by 5 mL PBS/l m o m NaCU75 mmom imidazole (pH 7.2). Retained scFv was eluted with 5 mL PBSll m o a NaCV300 m o V L imidazole (pH 7.2) and collected as I-mL fractions. Peak protein fractions were identified from the Azso and these were dialyzed against PBS before analysis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
Analysis of idiotope expression by a model scFv. This was performed by enzyme-linked immunosorbent assay (ELISA) using as a model the scFv from the murine B-cell lymphoma, BCL,, for which a panel of anti-idiotypic antibodies was available." Antibodies were coated to the wells of a microtiter plate using 50 pg/mL (rabbit polyclonal antibody) or 10 pg/mL (rat MoAbs). After washing, soluble hexahistidine-tagged scFv (25 pg/mL) expressed from V-genes of either the BCL, tumor or from V-genes of a control, the B1.8 murine hybridoma," was added. In addition, a positive control of IgM obtained from the BCL, tumor was used at 100 ng/mL. The detecting antibody was horseradish peroxidase (HRP)-goat-antimouse A (Southern Biotechnology Associates, Birmingham AL 35226) that recognizes the VA sequence of both the BCL, tumor and the B1.8 hybridoma."
Analysis of idiotope expression by a scFv from patients. For patients 1 and 8, rat anti-idiotypic MoAbs were available to test for idiotope expression by the SCFV protein. One of the MoAbs (9G4) has been described in detail": it recognizes a conformation-dependent idiotope expressed by Igs with VH encoded by the VH4-21 gene." The second MoAb (5H7). which has also been described, recognizes a private idiotope expressed by tumor cells of patient 1 .23 This first analysis was performed by dot blot, using the ProtoBlot AP system (Promega, Madison, WI); culture supernatant from bacteria transfected with each scFv-containing vector was applied to nitrocellulose, and then treated with the MoAb or control antibody (20 pg/ mL). Bound antibody was detected with alkaline phosphatase-labeled goat-antimouse IgG that can also detect rat IgG.
For patient 8, it was possible also to use an inhibition ELISA with the 9G4 MoAb for analyzing idiotope expression. Details of the assay have been rep~rted.'~ 
RESULTS
Analysis df clinical samples. Clinical material was obtained from 13 patients with B-cell tumors; this consisted of a lymph node biopsy in five cases, and blood in the remaining eight cases. The histologic or morphologic diagnoses ( Table   2) , which were made according to the Kiel classificati~n?~ indicate that there were six cases of follicular lymphoma involving cells of centroblastic and centrocytic morphology (FCCL), one of lymphocytic lymphoma, three of centrocytic lymphoma (CCL), and three of chronic lymphocytic leukemia (CLL). Phenotypic analysis (Table 2) showed that the tumor populations were monotypic with seven U+ and six A+. All expressed IgM at the cell surface and the cells from patients with CLL also expressed IgD, as did one case of FCCL. The percentages of tumor cells identifiable by monotypic light chain expression varied from 50% to 94% ( Table  2) . Expression of the CD5 antigen was variable.
V-gene sequence analysis of clinical samples. For analysis of V", samples of DNA were amplified with mixed V,BACK primers together with mixed J H primers, and the products cloned and sequenced. In the case of patients 4,9,10, and 12, cDNA was used for amplification; for this approach, the back primers used consisted of a mixture of VH-leader primers specific for the six VH families. For VL analysis of tumors, only the monotypic light chain known to be present from the cell phenotype was investigated. The Vu or VA primers were also used as mixtures together with the appropriate J primers ( Table 1) .
The results of sequencing the clones derived from the PCR amplifications are shown in Table 3 , and are presented as the number of repeated sequences, ie, those found in more than one clone, as compared with the number of clones analyzed. In the Table, the sequence analyses refer to one PCR amplification; in all cases, at least one further amplification product was analyzed, and similar patterns were obtained. When the starting material was not involved with tumor (reactive lymph node or normal spleen), all the sequences obtained were different, and there were no repeats. In contrast, for the 12 patients with lymphoma that were analyzed, repeated sequences were found in all. The number of repeated sequences varied between the tumors, partly because of differences in the degree of tumor infilmation (Table  2) , and also, probably more significantly, because of variation in the efficiency of priming. In the case of patient 6, involvement of the V&-21 gene was known because of reactivity of tumor tissue with the 9G4 MOA^:^ and the PCR product was sequenced directly without cloning.26 The V, gene of patient 12 was also sequenced directly.
Among the repeated VH sequences, a clonal relationship was seen by comparison of the CDR3 sequences. Although the clonal relationship was clear, in some cases of FCCL, there were some (up to 3) nucleotide differences between clones observed in independent amplifications, which could give rise to replacement amino acids. In contrast, for several patients in the CCL and CLL groups, all the clones had identical V, nucleotide sequences, consistent with low error rate expected only because of infidelity of Taq polymerase (1/5,000 per base p~lymerized).~' Therefore, it is likely that the differences observed in cases of follicular lymphoma reflect a real clonal heterogeneity characteristic of the cell of origin. Sequence heterogeneity has been analyzed in detail for patient 4, and has been reported elsewhere." For all patients, a predominant homogeneous sequence was readily apparent. To confirm the sequence, a second independent amplification was performed and the further V genes sequenced were found to have the same predominant sequence. Similar minor sequence heterogeneity was observed in the VL genes isolated from patients with FCCL; again details of this have been reported for patient 4," and in all cases, a major homogeneous sequence was seen. For the Vh genes, no identifiable sequence was obtained using material from patients 5 and 13. This probably indicates that the tumor cells were using a Vh gene that has not yet been identified.
The repeated V-gene sequences were suggestive of a tumor origin, and this was proved for three of the patient samples (patients 1,2, and 5). Anti-idiotypic antibodies had been raised that reacted specifically with the tumor cells from these patients, and the source of idiotypic Ig was via heterohybridomas established from their tumor cells.27 Therefore, it was possible to analyze the V-genes in the hybridomas, and in all three cases, these had the same V,, sequence as that identified by the repeated sequence from the tumor tissue. For patients 1 and 2, the VL sequences were also the same as that in the heterohybridoma (data not shown); as indicated above, the Vh sequence of patient 5 was unavailable.
The analysis of V,-gene sequences obtained as repeats and, therefore, assumed to be tumor-derived is shown in Table 4 . All the sequences contained no stop codons or frameshifts and therefore, are potentially functional. Sequences that have been submitted to the EMBL database (accession no. 2 3 1379 to 231398, and 231579) have been compared with the closest germline sequences available in the current databases. Although the numbers are small, there appears to be predominant involvement of VH3 (5/13), vH4 (6/13), and JH4 (8113). The For percent of sequence homologies with the closest germline genes are indicated in Table 4 , but because of polymorphisms in the germline genes:' further analysis of mutational patterns would require sequencing of the matched germline genes in the individual patients. In fact, this has been done for one case of FCCL (patient 4) and has been reported in detail. 29 The VH sequence showed a clear concentration of replacement mutations in the CDR sequences consistent with a role for antigen in selecting for certain amino acids. 29 The analysis of the VL sequences found as repeats is shown in Table 5 . These sequences have also been submitted to the EMBL database (accession no. 231379 to 231398). The Vh sequences from patients 5 and 13 are unavailable because of the failure to prime with current oligonucleotides.
Assembly, expression, and purijcation of scFv. The technique of PCR assembly avoids the use of multiple restriction enzymes that cut V genes at internal sites. The process described appears efficient and does not require the separate preparation of a linker fragment.30 The assembled products were cloned into the expression vector that included the c-myc tag (Fig 2) , and randomly picked clones were grown up and induced. Generally, Western blots using MoAb 9E10, specific for the c-myc protein, showed that 80% of the clones correctly expressed the assembled protein (data not shown). For ease of purification, the scFv was subcloned into the pRH2 expression vector that contains a hexahistidine tag. A clone from patient 8 was grown in a l-L volume, and the scFv was purified from the periplasm. Yield was estimated as 0.5 mg/LJOD, based on an A280 of 1.4 for a solution of 1 mg/mL. Analysis of idiotope expression by scFv. It was essential to test the ability of soluble SCFV to express idiotypic determinants, and for this analysis, an SCFV derived from the murine B-cell lymphoma (BCL,) that had been purified via the hexahistidine tag, as above, was used. A polyclonal anti-idiotypic antibody and a panel of five anti-idiotypic MoAbs had been raised against the tumor-derived IgM; 4/5 of the MoAbs were known to recognize idiotopes expressed by isolated heavy chain, but they failed to react with synthetic peptides based on the complementarity-determining regions, and therefore, appeared to be conformation-dependent?' One of the four MoAbs (MclO 9B 10) recognized the heavy chain idiotope only in combination with light chain:' and therefore, must be conformation-dependent. These antibodies were tested by ELISA for their ability to recognize the SCFV from the BCLl tumor, or a control scFv. Results (Fig 3) show that both the polyclonal antibody and 5/ 5 members of the MoAb panel recognized the expressed SCFV; no binding of control SCFV from the B 1.8 hybridomaz2 was detected (data not shown). Also, although it is difficult to compare the relative efficacy of binding of scFv with that of idiotypic IgM, the dilution curves for the two molecules were reasonably parallel (Fig 3) .
For patients 1 and 8, anti-idiotypic MoAbs were available.23 Using the dot blot technique, the SCFV from patient 1 reacted with the 5H7 MoAb that recognizes a private idiotope on this patient's tumor whereas the scFv from patient 8 did not react. In contrast, the scFv from patient 8 did react with the 9G4 MoAb that recognizes a conformationdependent idiotope expressed by Igs that use the VH4-21 gene. 24 The reactivity of the scFv from patient 8 with the 9G4 MoAb was confirmed using an idiotope-specific inhibition ELISA that has been described.23
DISCUSSION
To propose that patients with B-cell tumors should be treated by vaccination with personal vaccines containing idiotypic antigen from their tumor, there must be a simple, rapid, and effective method for producing such vaccines. This report sets out a molecular biologic method for approaching this, which starts with identification and isolation of the variable region genes from tumor biopsy material, and results in potential vaccines consisting of expressed protein or naked plasmid DNA.
Until now, to obtain idiotypic antigen from patient material for vaccination or for raising anti-idiotypic antibody it has been necessary to use the technique of cell hybridization." Using this approach, it was difficult to ensure that tumor-related idiotypic antigen had been isolated until the anti-idiotypic antibody was tested against the tumor cells. The molecular biologic approach appears to circumvent this problem in that identification of repeated sequences seems to be relatively simple. Confidence that these repeats derive from tumor arises from the fact that such repeats were not seen using normal or reactive lymphoid tissue as a source. Also, derivation from tumor cells was proved in the 3/3 cases for which a tumor-derived immortalized cell line, which had been used to raise specific anti-idiotypic antibody, was available. When using DNA as a source, it is possible that aberrantly rearranged V-genes from the allelic chromosome would be amplified. However, in no case was there a dual set of repeats, indicating that this may not be a problem. There may be several reasons for obtaining only one product; first, there may have been only one V-gene rearrangement, with the allelic chromosome remaining in germline configuration. In fact, for VH genes of B-cell tumors the frequency of biallelic rearrangement has been estimated at s+O%.~I A further possible reason in the case of the follicular lymphomas, might be that the primers used would not amplify from a chromosome that has undergone a t region.3z Finally, the primers were designed to avoid at least some pseudogenes. However, if two repeated sequences did result from the PCR, they should be distinguishable by the presence in the aberrant gene of stop codons, frameshifts, or other causes of nonfunctional genes.
Follicular lymphomas are considered to be tumors of germinal center B cells, and it is in this area of the lymph node that somatic hypermutation occurs.33 Therefore, it should be expected that the malignant cells may retain the ability to undergo somatic hypermutation and even be selected by antigen.34 Clonal heterogeneity could result, and has in fact been observed in V-gene sequences from patient 4 with follicular lymphoma, who had the highest number of somatic mutation~.~' However, there was a clear major sequence that was found in the majority of clones and would provide the sequence for assembly. In fact, with vaccination, which should induce a polyclonal immune response, the loss of one amino acid that could have contributed to an idiotypic determinant would have only a limited effect.' Success of the use of scFv as a idiotypic protein vaccine may depend on the correct folding of the molecule to display idiotypic determinants. The ability to generate scFv molecules with antibody activity indicates that such folding does occur." By using the murine B-cell lymphoma, BCL,, for which a panel of anti-idiotypic MoAbs was available, we were able to show that tumor-derived scFv, expressed in bacteria, retained idiotypic determinants recognized by 515 of the anti-idiotypic MoAbs and by a polyclonal antibody, thereby allowing the option of using expressed scFv as a vaccine. For the scFv preparations from patients, it was possible to show that for the two cases where anti-idiotypic antibodies were available, the proteins expressed in bacteria were specifically recognized by the antibodies. However, it may turn out that expression of protein is not required for vaccine construction. The use of naked plasmid DNA-encoding viral nucleoprotein as a vaccine to provide protective immunity in mice against influenza A virus has been reported." In the model described, both antibody and cytotoxic T lymphocytes were induced, indicating that it may not be necessary to express antigens as proteins before For personal use only. on August 30, 2017. by guest www.bloodjournal.org From vaccination. Indeed, it has been known for some time that directly injected DNA can survive in muscle cells and that encoded protein can be produced.36 Events occurring in the muscle cell that result in presentation of antigen to the immune system are not yet understood, but it has been reported that myoblasts can be induced by cytokines to express MHC class I1 antigens, and that they are then able to present protein antigens."
With regard to an idiotypic vaccine, we have so far found that intramuscular injection of a naked plasmid, encoding the scFv from the BCL, tumor, was able to induce antiidiotypic antibody in syngeneic mice, and that the antibody could recognize idiotypic IgM either by ELISA or expressed by the tumor cells.22 Experiments are in progress to refine the vectors and to assess the ability of the naked DNA to induce protective immunity against lymphoma, which, in the case of idiotypic IgM antigen, is mediated largely by antiidiotypic antibody? Clearly there are several options for designing the final vaccine vehicle, and there is potential for including additional molecules that encode cytokines or adhesion molecules in the vector, to stimulate the immune response further. For B-cell lymphoma, at least the preliminary steps have been taken for application of a novel treatment of this inexorable tumor.
